Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Overview of attention for article published in Frontiers in oncology, November 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,513 followers.

New research: Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study: Objective We investigated lenvatinib plus programmed cell death-1 (PD-1)… https://t.co/KRDwM

24 Nov 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.